Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
FD4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. (FDMT)

NASDAQ Global Select · Currency in USD
$10.80 ▼ -1.05 (-8.86%)
At close: Oct 23, 4:00 PM ET. Market closed.
$10.80 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:45 PM ET

Summary

Previous Close
$11.85
Open
$11.74
Day's Range
$10.68 – $11.74
52 Week Range
$6.96 – $16.93
Volume
996,095
Avg. Volume
990,954
Market Cap
$596.64M
Beta (5Y Monthly)
2.74
PE Ratio (TTM)
--
EPS (TTM)
-$2.55
Earnings Date
Nov 10, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$29.67

Profile: 4D Molecular Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
196
CEO
David H. Kirn

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease.

Earnings

Next report: Tue, Nov 10, 2026
EPS estimate -$1.04 · Revenue est. $4.13M
DateEst.Actual
Aug 13, 2026-$1.02-$1.04Miss
May 7, 2026-$0.97-$1.01Miss
Mar 18, 2026-$0.53$0.43Beat
Nov 10, 2025-$1.02-$1.01Beat
Aug 11, 2025-$0.88-$0.98Miss
May 8, 2025-$0.84-$0.86Miss

Analyst view

Consensus price target
$29.67 ▲ +174.7%
Range $20.00 – $37.00
Rating: Buy
Buy 79% · Hold 14% · Sell 7%

Get free alerts on FDMT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.